 OSAKA, Japan CAMBRIDGE, Mass.--BUSINESS WIRE--Takeda Pharmaceutical Company Limited TSE:4502NYSE:TAK Takeda today announced the U.S. Food and Drug Administration FDA Antimicrobial Drugs Advisory Committee AMDAC voted unanimously to recommend use of maribavir TAK-620 for the treatment of refractory cytomegalovirus CMV infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients. The committee also voted unanimo 